Moleculin Biotech completes enrollment in Part A of Phase 2/3 AML trial
Moleculin Biotech (MBRX) completed enrollment in Part A of its Phase 2/3 relapsed/refractory AML MIRACLE trial, keeping the program on track for a Q1 2027 data readout.
Moleculin Biotech (MBRX) completed enrollment in Part A of its Phase 2/3 relapsed/refractory AML MIRACLE trial, keeping the program on track for a Q1 2027 data readout.